Table 2.
Tumor Doubling Rates in Patients Who Underwent Active Surveillance Pre- and Post-PE-M in Stratified Based on Patient Age at Time of Presentation
| No. of patients | Tumor doubling rate (per year) |
|||||
|---|---|---|---|---|---|---|
| >0.5, n (%) | 0.1–0.5, n (%) | −0.1 to 0.1, n (%) | <−0.1, n (%) | |||
| Pre-PE-M | <40 Years | 12 | 7 (58.3) | 5 (41.7) | 0 | 0 |
| Post-PE-M | <40 Years | 15 | 1 (6.7) | 2 (13.3) | 5 (33.3) | 7 (46.7) |
| Pre-PE-M | 40–59 Years | 29 | 15 (51.7) | 13 (44.8) | 0 | 1 (3.5) |
| Post-PE-M | 40–59 Years | 31 | 4 (12.9) | 5 (16.1) | 11 (35.5) | 11 (35.5) |
| Pre-PE-M | ≥60 Years | 28 | 13 (46.5) | 14 (50.0) | 1 (0.5) | 0 |
| Post-PE-M | ≥60 Years | 32 | 1 (3.1) | 3 (9.4) | 9 (28.1) | 19 (59.4) |
Results of statistical analysis for pre-PE-M versus post-PE-M: p < 0.001 (≤40 years), p < 0.001 (41–59 years), p < 0.001 (≥60 years). Pre: p = 0.918 (≤40 years vs. 41–59 years), p = 0.539 (41–59 years vs. ≥60 years). Post: p = 0.861 (≤40 years vs. 41–59 years), p = 0.202 (41–59 years vs. ≥60 years).